Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Understanding anxiety in adults on the autism spectrum: An investigation of its relationship with intolerance of uncertainty, sensory sensitivities and repetitive behaviours.

Hwang YIJ, Arnold S, Srasuebkul P, Trollor J.

Autism. 2019 Aug 15:1362361319868907. doi: 10.1177/1362361319868907. [Epub ahead of print]

PMID:
31416327
2.

Mortality and cause of death of Australians on the autism spectrum.

Hwang YIJ, Srasuebkul P, Foley KR, Arnold S, Trollor JN.

Autism Res. 2019 May;12(5):806-815. doi: 10.1002/aur.2086. Epub 2019 Feb 25.

PMID:
30802364
3.

Epidemiology of gastrostomy insertion for children and adolescents with intellectual disability.

Wong K, Leonard H, Pearson G, Glasson EJ, Forbes D, Ravikumara M, Jacoby P, Bourke J, Srasuebkul P, Trollor J, Wilson A, Nagarajan L, Downs J.

Eur J Pediatr. 2019 Mar;178(3):351-361. doi: 10.1007/s00431-018-3304-x. Epub 2018 Dec 15.

PMID:
30554367
4.

Evolving Trends of Gastrostomy Insertion Within a Pediatric Population.

Glasson EJ, Wong K, Leonard H, Forbes D, Ravikumara M, Mews C, Jacoby P, Bourke J, Trollor J, Srasuebkul P, Wilson A, Nagarajan L, Downs J.

J Pediatr Gastroenterol Nutr. 2018 Nov;67(5):e89-e94. doi: 10.1097/MPG.0000000000002042.

PMID:
29851763
5.

Insights from linking routinely collected data across Australian health jurisdictions: a case study of end-of-life health service use.

Langton JM, Goldsbury D, Srasuebkul P, Ingham JM, O'Connell DL, Pearson SA.

Public Health Res Pract. 2018 Mar 15;28(1). pii: 2811806. doi: 10.17061/phrp2811806.

6.

Emergency department presentation and readmission after index psychiatric admission: a data linkage study.

Li X, Srasuebkul P, Reppermund S, Trollor J.

BMJ Open. 2018 Feb 28;8(2):e018613. doi: 10.1136/bmjopen-2017-018613.

7.

Health care use and costs at the end of life: a comparison of elderly Australian decedents with and without a cancer history.

Reeve R, Srasuebkul P, Langton JM, Haas M, Viney R, Pearson SA; EOL-CC study authors.

BMC Palliat Care. 2017 Jun 21;17(1):1. doi: 10.1186/s12904-017-0213-0. Erratum in: BMC Palliat Care. 2017 Oct 10;16(1):51.

8.

Cohort profile: a data linkage cohort to examine health service profiles of people with intellectual disability in New South Wales, Australia.

Reppermund S, Srasuebkul P, Heintze T, Reeve R, Dean K, Emerson E, Coyne D, Snoyman P, Baldry E, Dowse L, Szanto T, Sara G, Florio T, Trollor JN.

BMJ Open. 2017 Apr 12;7(4):e015627. doi: 10.1136/bmjopen-2016-015627.

9.

Cause of death and potentially avoidable deaths in Australian adults with intellectual disability using retrospective linked data.

Trollor J, Srasuebkul P, Xu H, Howlett S.

BMJ Open. 2017 Feb 7;7(2):e013489. doi: 10.1136/bmjopen-2016-013489.

10.

Validating a proxy for disease progression in metastatic cancer patients using prescribing and dispensing data.

Joshi V, Adelstein BA, Schaffer A, Srasuebkul P, Dobbins T, Pearson SA; Elements of Cancer Care (EoCC) Investigators.

Asia Pac J Clin Oncol. 2017 Oct;13(5):e246-e252. doi: 10.1111/ajco.12602. Epub 2016 Sep 26.

PMID:
27665738
11.

Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer.

Parkinson B, Viney R, Haas M, Goodall S, Srasuebkul P, Pearson SA.

Pharmacoeconomics. 2016 Oct;34(10):1039-50. doi: 10.1007/s40273-016-0411-2.

PMID:
27207252
12.

Health service use and costs in the last 6 months of life in elderly decedents with a history of cancer: a comprehensive analysis from a health payer perspective.

Langton JM, Reeve R, Srasuebkul P, Haas M, Viney R, Currow D, Pearson SA.

Br J Cancer. 2016 May 24;114(11):1293-302. doi: 10.1038/bjc.2016.75. Epub 2016 Apr 26.

13.

Resource use, costs and quality of end-of-life care: observations in a cohort of elderly Australian cancer decedents.

Langton JM, Srasuebkul P, Reeve R, Parkinson B, Gu Y, Buckley NA, Haas M, Viney R, Pearson SA; End-of-Life in Cancer Care (EoL-CC) Investigators.

Implement Sci. 2015 Feb 26;10:25. doi: 10.1186/s13012-014-0148-2.

14.

Antidepressant therapy in cancer patients: initiation and factors associated with treatment.

Pearson SA, Abrahamowicz M, Srasuebkul P, Buckley NA.

Pharmacoepidemiol Drug Saf. 2015 Jun;24(6):600-9. doi: 10.1002/pds.3753. Epub 2015 Apr 8.

PMID:
25858166
15.

Can administrative data be used to measure chemotherapy side effects?

Pearce A, Haas M, Viney R, Haywood P, Pearson SA, van Gool K, Srasuebkul P, Ward R.

Expert Rev Pharmacoecon Outcomes Res. 2015 Apr;15(2):215-22. doi: 10.1586/14737167.2015.990888. Epub 2014 Dec 11.

PMID:
25495682
16.

Lymphoid neoplasm incidence by WHO subtype in Australia 1982-2006.

van Leeuwen MT, Turner JJ, Joske DJ, Falster MO, Srasuebkul P, Meagher NS, Grulich AE, Giles GG, Vajdic CM.

Int J Cancer. 2014 Nov 1;135(9):2146-56. doi: 10.1002/ijc.28849. Epub 2014 Apr 2.

17.

Trastuzumab therapy in Australia: which patients with HER2+ metastatic breast cancer are assessed for cardiac function?

Lu CY, Srasuebkul P, Drew AK, Chen K, Ward RL, Pearson SA.

Breast. 2013 Aug;22(4):482-7. doi: 10.1016/j.breast.2013.04.011. Epub 2013 May 9.

PMID:
23664254
18.

Validation of a proxy for estrogen receptor status in breast cancer patients using dispensing data.

Srasuebkul P, Dobbins TA; Elements of Cancer Care (EoCC) Investigators, Pearson SA.

Asia Pac J Clin Oncol. 2014 Jun;10(2):e63-8. doi: 10.1111/ajco.12015. Epub 2012 Nov 26.

PMID:
23176304
19.

Serum macrophage inhibitory cytokine-1 (MIC-1/GDF15): a potential screening tool for the prevention of colon cancer?

Brown DA, Hance KW, Rogers CJ, Sansbury LB, Albert PS, Murphy G, Laiyemo AO, Wang Z, Cross AJ, Schatzkin A, Danta M, Srasuebkul P, Amin J, Law M, Breit SN, Lanza E.

Cancer Epidemiol Biomarkers Prev. 2012 Feb;21(2):337-46. doi: 10.1158/1055-9965.EPI-11-0786. Epub 2011 Dec 5.

20.

Positive spillover effects of prescribing requirements: increased cardiac testing in patients treated with trastuzumab for HER2+ metastatic breast cancer.

Lu CY, Srasuebkul P, Drew AK, Ward RL, Pearson SA.

Intern Med J. 2012 Nov;42(11):1229-35. doi: 10.1111/j.1445-5994.2011.02604.x.

PMID:
21981464
21.

Antiretroviral therapy outcomes of HIV-infected children in the TREAT Asia pediatric HIV observational database.

Hansudewechakul R, Sirisanthana V, Kurniati N, Puthanakit T, Lumbiganon P, Saphonn V, Yusoff NK, Kumarasamy N, Fong SM, Nallusamy R, Srasuebkul P, Law M, Sohn AH, Chokephaibulkit K; TREAT Asia Pediatric HIV Observational Database.

J Acquir Immune Defic Syndr. 2010 Dec;55(4):503-9. doi: 10.1097/QAI.0b013e3181f5379a.

22.

Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study.

Puls RL, Srasuebkul P, Petoumenos K, Boesecke C, Duncombe C, Belloso WH, Molina JM, Li L, Avihingsanon A, Gazzard B, Cooper DA, Emery S; Altair Study Group.

Clin Infect Dis. 2010 Oct 1;51(7):855-64. doi: 10.1086/656363.

PMID:
20735258
23.

Patient Characteristics and Treatment Outcome Associated with Protease Inhibitor (PI) use in the Asia-Pacific Region.

Pujari S, Srasuebkul P, Sungkanuparph S, Lim PL, Kumarasamy N, Chuah J, Kumar RN, Chen YM, Oka S, Choi JY, Lee MP, Phanuphak P, Kamarulzaman A, Lee C, Fujie Z, Ditangco R, Saphonn V, Sirisanthana T, Merati TP, Smith J, Law MG.

J Antivir Antiretrovir. 2009 Nov 1;1(1):28-35.

24.

Short-term clinical disease progression in HIV-infected patients receiving combination antiretroviral therapy: results from the TREAT Asia HIV observational database.

Srasuebkul P, Lim PL, Lee MP, Kumarasamy N, Zhou J, Sirisanthana T, Li PC, Kamarulzaman A, Oka S, Phanuphak P, Vonthanak S, Merati TP, Chen YM, Sungkanuparph S, Tau G, Zhang F, Lee CK, Ditangco R, Pujari S, Choi JY, Smith J, Law MG.

Clin Infect Dis. 2009 Apr 1;48(7):940-50. doi: 10.1086/597354.

25.

Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection.

NĂ¼esch R, Ananworanich J, Srasuebkul P, Chetchotisakd P, Prasithsirikul W, Klinbuayam W, Mahanontharit A, Jupimai T, Ruxrungtham K, Hirschel B.

AIDS. 2008 Jan 2;22(1):152-4.

PMID:
18090405
26.

Impact of drug classes and treatment availability on the rate of antiretroviral treatment change in the TREAT Asia HIV Observational Database (TAHOD).

Srasuebkul P, Calmy A, Zhou J, Kumarasamy N, Law M, Lim PL; TREAT Asia HIV Observational Database.

AIDS Res Ther. 2007 Sep 17;4:18. doi: 10.1186/1742-6405-4-18.

27.

Prior antiretroviral therapy experience protects against zidovudine-related anaemia.

Huffam SE, Srasuebkul P, Zhou J, Calmy A, Saphonn V, Kaldor JM, Ditangco R; TREAT Asia HIV Observational Database (TAHOD).

HIV Med. 2007 Oct;8(7):465-71.

28.

Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.

Srasuebkul P, Ungsedhapand C, Ruxrungtham K, Boyd MA, Phanuphak P, Cooper DA, Law MG.

HIV Med. 2007 Jan;8(1):46-54.

29.

Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz.

Boyd MA, Carr A, Ruxrungtham K, Srasuebkul P, Bien D, Law M, Wangsuphachart S, Krisanachinda A, Lerdlum S, Lange JM, Phanuphak P, Cooper DA, Reiss P.

J Infect Dis. 2006 Sep 1;194(5):642-50. Epub 2006 Jul 18. Erratum in: J Infect Dis. 2006 Sep 15;194(6):870. Dosage error in article text.

PMID:
16897663
30.

Monitoring the toxicity of antiretroviral therapy in resource limited settings: a prospective clinical trial cohort in Thailand.

Nuesch R, Srasuebkul P, Ananworanich J, Ruxrungtham K, Phanuphak P, Duncombe C; HIV-NAT Study Team.

J Antimicrob Chemother. 2006 Sep;58(3):637-44.

PMID:
16895939
31.

Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).

Boyd MA, Srasuebkul P, Khongphattanayothin M, Ruxrungtham K, Hassink EA, Duncombe CJ, Ubolyam S, Burger DM, Reiss P, Stek M Jr, Lange J, Cooper DA, Phanuphak P.

Antivir Ther. 2006;11(2):223-32.

PMID:
16640103
32.

Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir.

Boyd MA, Srasuebkul P, Ruxrungtham K, Mackenzie PI, Uchaipichat V, Stek M Jr, Lange JM, Phanuphak P, Cooper DA, Udomuksorn W, Miners JO.

Pharmacogenet Genomics. 2006 May;16(5):321-9.

PMID:
16609363
33.

The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.

Cardiello P, Srasuebkul P, Hassink E, Mahanontharit A, Samor T, Ruxrungtham K, Lange J, Cooper D, Phanuphak P.

HIV Med. 2005 Mar;6(2):122-8.

34.

A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection.

Cardiello PG, Hassink E, Ananworanich J, Srasuebkul P, Samor T, Mahanontharit A, Ruxrungtham K, Hirschel B, Lange J, Phanuphak P, Cooper DA.

Clin Infect Dis. 2005 Feb 15;40(4):594-600. Epub 2005 Jan 26.

PMID:
15712083
35.

Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection.

Ungsedhapand C, Srasuebkul P, Cardiello P, Ruxrungtham K, Ratanasuwan W, Kroon ED, Tongtalung M, Juengprasert N, Ubolyam S, Siangphoe U, Emery S, Lange JM, Cooper DA, Phanuphak P; HIV-NAT 002 and HIV-NAT 003 Study Team.

J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):693-701.

PMID:
15167288
36.

In vivo cell-mediated immunity in subjects with undetectable viral load on protease inhibitor-based versus non-protease inhibitor-based highly active antiretroviral therapy.

Ananworanich J, Nuesch R, Teeratakulpisarn S, Srasuebkul P, Chuenyam T, Siangphoe U, Ungsedhaphand C, Phanuphak P, Ruxrungtham K.

J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):570-2. No abstract available.

PMID:
12679711
37.

Impact of particulate air pollutants on allergic diseases, allergic skin reactivity and lung function.

Pothikamjorn SL, Ruxrungtham K, Thampanitchawong P, Fuangthong R, Srasuebkul P, Sangahsapaviriyah A, Suttithavil W, Klaewsongkram J, Parisuthikul V, Viravan T, Rumsaeng V, Kana K, Direkwattanachai C, Kamchaisathien V, Phanupak P.

Asian Pac J Allergy Immunol. 2002 Jun;20(2):77-83.

38.

Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study.

Cardiello PG, van Heeswijk RP, Hassink EA, Srasuebkul P, Mahanontharit A, Samor TM, Worarien W, Beijnen JH, Hoetelmans RM, Ruxrungtham K, Cooper DA, Lange JM, Phanuphak P.

J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):464-70.

PMID:
11981362

Supplemental Content

Loading ...
Support Center